International Overdose Awareness Day
31 August 2020

David Bayever
Central Drug Authority (CDA)

• The Central Drug Authority (CDA) is a statutory body, established in terms of the Prevention of and Treatment for Substance Abuse Act, No.70 of 2008

• National Drug Master Plan 2019-2024 has recognised key issues that act as barriers to reduce overdose for people who use drugs, and includes measures to ensure a person-centered approach to reducing overdoses.
Drug abuse always carries the risk of serious side effects, including overdose. Whether you abuse alcohol cocaine, or medications—such as opioid painkillers—addiction development will always be a concern. If substance use behaviour persists, there remains a real possibility of a drug overdose.
Some Stats

• The total number of deaths due to drug overdose rose more than twofold from 2002 to 2015
• According to a 2016 report from the Centre for Disease Control and Prevention (CDC), the number of opioid-related deaths has increased by 200% since 2000
• In Amsterdam, the number of deaths resulting from drug overdoses decreased by almost a quarter between 2010 and 2011, down to 64 fatal overdoses.
NDMP Principles and Goals

• Demand Reduction: aimed at discouraging the onset of use and abuse of substances
• Supply reduction: aimed at stopping the production, distribution of illicit substances through law enforcement
• Harm reduction: holistic treatment of users and mitigating the social, psychological and health impact of substance abuse
  – NSP; OAT; HTS; HIV and STI prevention
NDMP Principles and Goals

Services to lessen the harmful consequences of opioid use disorders which prevent opioid overdose deaths, not directly linked to blood-borne infections, are recommended by the WHO for people who inject drugs.

- Principle 4: People centered
- Principle 5: Inclusive and participatory
- recommending access to naloxone, where peers and potential first responders, including family are trained in administration of Medically Assisted Treatment (MAT) in case of overdose
Goals of the NDMP 2019 - 2024

- Goal 3: Increase the availability of and access to controlled substances exclusively for medical and scientific purposes, while preventing their diversion
  - implementing Opioid Agonist/Substitution Treatment (OA/ST), such as methadone and buprenorphine for PWUD and PWID
  - emergency management of opioid, including heroin, overdose programmes
• THANK YOU FOR YOUR ATTENTION